Denosumab Patent
This MDL consolidates Biologics Price Competition and Innovation Act litigation brought by the manufacturer of the branded denosumab biologics against multiple biosimilar developers over patents covering the reference products. Centralized in the District of New Jersey in 2025, the docket sits within a broader, multi-year patent-assertion campaign asserting dozens of patents across five separate BPCIA lawsuits filed against different biosimilar developers, several of which had already settled on individually negotiated terms before this MDL was formed to coordinate the remaining, later-filed actions. The docket carries 8 pending actions.
What drives resolution in a docket like this is a defendant-by-defendant settlement negotiation process running in parallel with active litigation against the defendants who have not yet settled, rather than a single docket-wide trial or ruling. Settlements in this category of dispute typically specify a negotiated market-entry date for the settling biosimilar developer, sometimes earlier under specified conditions, allowing the branded manufacturer to manage the pace of biosimilar competition across its franchise while litigation continues against remaining defendants on the same or related patents.
For anyone tracking how large biosimilar patent-assertion campaigns unfold across multiple related MDLs and individual actions, this docket illustrates the settlement-sequencing pattern common to this category: negotiated, staggered market-entry settlements with some defendants while litigation continues against others, all coordinated for pretrial efficiency even though each defendant's ultimate outcome may differ. Criterica Intelligence's platform tracks this settlement-sequencing structure across biosimilar and other patent-assertion campaigns rather than treating a single MDL in isolation from the broader litigation program it is part of.
The manufacturer of the branded denosumab biologics, used for bone-density conditions and to prevent cancer-related skeletal events, alleges that multiple biosimilar developers' proposed follow-on products infringe patents covering the reference biologics.
Several biosimilar developers named in the broader multi-year patent-assertion campaign had already settled on individually negotiated terms before this MDL was formed, which consolidated only the later-filed actions still being actively litigated.
A defendant-by-defendant settlement negotiation process running in parallel with continued litigation against defendants who have not yet reached terms, rather than a single ruling or trial resolving every defendant's exposure at once.
That a branded manufacturer can manage a multi-year, multi-defendant campaign through staggered, negotiated settlements with some parties while continuing to litigate against others, a settlement-sequencing pattern Criterica Intelligence tracks across biosimilar and other patent-assertion programs.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.